TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- Tempus AI
- 入组人数
- 500
- 试验地点
- 32
- 主要终点
- Changes in ctDNA from baseline, on-treatment and post-treatment blood samples.
研究概览
简要总结
This study is a non-interventional, multicenter, multicohort evaluation of participants with cancer who will undergo longitudinal plasma ctDNA biomarker profiling at specific time points in addition to standard of care therapy.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥18 years of age
- •Willing to participate in the research
- •Able to provide informed consent
- •Must be diagnosed with cancer
排除标准
- •1. Not willing or able to have additional blood samples collected
研究组 & 干预措施
Cohort 001: KRAS mutated CRC
No intervention.
Cohort 002: KRAS mutated PDAC
No intervention.
Cohort 003: KRAS mutated NSCLC
No intervention.
Cohort 004: Gastric 1L Plus
No intervention.
Cohort 005: mCRPC 1L Plus
No intervention.
Cohort 006: Pan Tumor ADCs
No intervention.
Cohort 007: Stage III-IV EGFR Activating Mutation NSCLC
No intervention.
结局指标
主要结局
Changes in ctDNA from baseline, on-treatment and post-treatment blood samples.
时间窗: 5 years
Assess ctDNA kinetics using ctDNA clearance factors such as time to clearance, best overall clearance rate, best confirmed clearance, and time to ctDNA recurrence and correlate with standard of care therapy real-world outcomes such as overall survival, progression-free survival, time to next treatment, and time to treatment discontinuation.
次要结局
- Generation of DNA, RNA, immune and other multiomic datasets.(5 years)